Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers

• Type: Another Publication in an International Scientific Journal
• Date: 2014

Authors

Lima, A (Author) Other; Sousa, H (Author) Other; Monteiro, J (Author) Other; Azevedo, R (Author) Other; Rui Medeiros (Author) ICBAS; Seabra, V (Author) Other

Journal

Title: Pharmacogenomics

Vol. 15

Pages: 1611-1635

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 15 Citations

Scopus - 18 Citations

Other information

Authenticus ID: P-009-WRC

DOI: 10.2217/pgs.14.116

Abstract (EN): Methotrexate (MTX) is used in low doses to treat a variety of diseases. Although the mechanism responsible for its therapeutic action is unknown, MTX membrane transport proteins (influx and/or efflux) can be major determinants of pharmacokinetics, adverse drug reactions and clinical response profiles. With progess in pharmacogenomics, the improvement of the prediction of patients' therapeutic outcome treated with low doses of MTX will offer a powerful tool for the translation of transporter SNPs into clinical practice and will be essential to sustain a breakthrough in the field of personalized medicine. Therefore, this paper provides an update on the current data on SNPs in genes encoding low-dose MTX membrane transport proteins and their relevance as possible biomarkers of MTX therapeutic outcome.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 25